Zogenix gains Breakthrough status, but GW Pharma still ahead in Dravet syndromeThe FDA has granted Zogenix a Breakthrough Therapy Designation for its pipeline product, ZX008 for the treatment of seizures associated with Dravet syndrome. Share XZogenix gains Breakthrough status, but GW Pharma still ahead in Dravet syndromehttps://pharmaphorum.com/news/zogenix-gains-breakthrough-status-but-gw-pharma-still-ahead-in-dravet-syndrome/